Compare Kohl's Corporation (KSS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Novo Nordisk A/S — how do they compare? Kohl's Corporation trades at $20.36 (market cap $2.28B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 72.5× Kohl's Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Novo Nordisk A/S for 116 Days on average.
| KSS | NVO | |
|---|---|---|
Market Cap | $2.28B | $165.31B |
Volume | 4,960,280 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $63.98 |
52-Week Low | $11.72 | $35.29 |
Typical Hold Time | 48 Days | 116 Days |
Enterprise Value | $7.88B | $179.56B |
Dividend Yield | 2.49% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $20.28, up 0.8% with a bullish technical signal despite overbought RSI readings. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, while recent earnings beats and raised guidance signal operational improvement. However, revenue has declined for 18 consecutive quarters, presenting a challenging growth environment.
The investment case balances deep value against persistent sales declines. While low valuations and margin improvements support upside potential, sustained revenue weakness and competitive pressures remain key risks. Analyst consensus is mixed with 30% buy ratings but a $15.50 price target below current levels, suggesting cautious optimism.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
